Shannon; Dean

Patent Applications and Registrations

Patent applications and USPTO patent grants for Shannon; Dean.The latest application filed is for "inhibitors of influenza viruses replication".

Company Profile

1.13.11

Shannon; Dean - Richibucto Road CA
Shannon; Dean - Milford MA

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
Inhibitors of influenza viruses replication Grant 10,273,233 - Farmer , et al.	2019-04-30
Inhibitors Of Influenza Viruses Replication App 20180065963 - Farmer; Luc J. ; et al.	2018-03-08
Solid forms of gyrase inhibitor (R)-1-ethyl-3-[6-fluoro-5-[2-(1-hydroxy-1-methyl-ethyl)pryimidin-5-yl]-7-- (tetrahydrofuran-2-yl)-1H-benzimidazol-2-yl]urea Grant 9,040,542 - Shannon , et al. May 26, 2	2015-05-26
Process of making gyrase and topoisomerase inhibitors Grant 8,912,326 - Shannon , et al. December 16, 2	2014-12-16
Solid Forms Of Gyrase Inhibitor (r)-1-ethyl-3-[5-[2-(1-hydroxy-1-methyl-ethyl)pyrimidin-5-yl]-7-(tetrahyd- Rofuran-2-yl]-1h-benzimidazol-2-yl]urea App 20130317222 - Shannon; Dean ; et al.	2013-11-28
Solid Forms Of Gyrase Inhibitor (r)-1-ethyl-3-[6-fluoro-5-[2-(1-hydroxy-1-methyl-ethyl)pyrimidin-5-yl]-7-- (tetrahydrofuran-2-yl)-1h-benzimidazol-2-yl]urea App 20130267540 - Shannon; Dean ; et al.	2013-10-10
Process Of Making Gyrase And Topoisomerase Inhibitors App 20130261305 - Shannon; Dean ; et al.	2013-10-03
c-MET protein kinase inhibitors Grant 8,481,524 - Lauffer , et al. July 9, 2	2013-07-09
Solid forms of gyrase inhibitor (R)-1-ethyl-3-[5-[2-(1-hydroxy-1-methyl-ethyl)pyrimidin-5-YL]-7-(tetrahyd- rofuran-2-yl)-1H-benzimidazol-2-YL]urea Grant 8,481,552 - Shannon , et al. July 9, 2	2013-07-09
Solid forms of gyrase inhibitor (R)-1-ethyl-3-[6-fluoro-5-[2-(1-hydroxy-1-methyl-ethyl)pyrimidin-5-yl]-7-- (tetrahydrofuran-2-yl)-1H-benzimidazol-2-yl]urea Grant 8,476,281 - Shannon , et al. July 2, 2	2013-07-02
Process of making gyrase and topoisomerase IV inhibitors Grant 8,471,014 - Shannon , et al. June 25, 2	2013-06-25
Triazolothiadiazole inhibitor of c-Met protein kinase Grant 8,343,998 - Lauffer , et al. January 1, 2	2013-01-01
Solid Forms Of Gyrase Inhibitor (r)-1-ethyl-3-[5-[2-(1-hydroxy-methyl-ethyl)pyrimidin-5-yl]-7-(tetrahydro- Furan-2-yl)-1h-benzimidazol-2-yl]urea App 20120184741 - Shannon; Dean ; et al.	2012-07-19
Solid Forms Of Gyrase Inhibitor (r)-1-ethyl-3-[6-fluoro-5-[2-(1-hydroxy-1-methyl-ethyl)pyrimidin-5-yl]-7-- (tetrahydrofuran-2-yl)-1h-benzimidazol-2-yl]urea App 20120184564 - Shannon; Dean ; et al.	2012-07-19
Process Of Making Gyrase And Topoisomerase Iv Inhibitors App 20120184742 - Shannon; Dean ; et al.	2012-07-19
Triazolothiadiazole inhibitor of c-Met protein kinase Grant 8,217,056 - Lauffer , et al. July 10, 2	2012-07-10
Triazolothiadiazole Inhibitor Of C-met Protein Kinase App 20110301195 - Lauffer; David ; et al.	2011-12-08
Triazolothiadiazole Inhibitor Of C-met Protein Kinase App 20110207774 - Lauffer; David ; et al.	2011-08-25
C-met Protein Kinase Inhibitors App 20110136789 - Lauffer; David ; et al.	2011-06-09
Triazolothiadiazole Inhibitor Of C-met Protein Kinase App 20100234423 - Lauffer; David ; et al.	2010-09-16

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.